Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Profile Name | ROS1 L2026M |
Gene Variant Detail | |
Relevant Treatment Approaches |
Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|---|
ROS1 L2026M | Advanced Solid Tumor | predicted - sensitive | Foritinib | Preclinical - Biochemical | Actionable | In a preclinical study, Foritinib inhibited kinase activity of a transformed cell line expressing ROS1 L2026M in culture (PMID: 32918045). | 32918045 | |
ROS1 L2026M | Advanced Solid Tumor | predicted - sensitive | Lorlatinib | Preclinical - Biochemical | Actionable | In a preclinical study, Lorbrena (lorlatinib) inhibited kinase activity of a transformed cell line expressing ROS1 L2026M in culture (PMID: 32918045). | 32918045 |